Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

BACKGROUND: The PI3K-Akt pathway is frequently activated in acute leukemias and represents an important therapeutic target. UCN-01 and perifosine are known to inhibit Akt activation. METHODS: The primary objective of this phase I study was to determine the maximum tolerated dose (MTD) of UCN-01 give...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gojo, Ivana, Perl, Alexander, Luger, Selina, Baer, Maria R., Norsworthy, Kelly J., Bauer, Kenneth S., Tidwell, Michael, Fleckinger, Stephanie, Carroll, Martin, Sausville, Edward A.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3723766/
https://ncbi.nlm.nih.gov/pubmed/23443507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9937-8
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki